Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.22 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 285 | 0.91 |
| pathways Reactome | 4 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 1927
Sealed predictions
- ABL2 in dopamine neurons, braak+0.64 (p 0.063) → +0.58 (p 0.101)receipt 1933
Swarm cases
receipt 1933: ABL2 in dopamine neurons, braak
- power
- full sample +0.42 (p 0.084, n 18), 95% CI -0.06 to +0.74. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.52 (p 0.028, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.46 (p 0.056, n 18). could be the mix.
- skeptic
- leave-one-out range +0.34 to +0.56, sign flips 0; without severely affected donors +0.42 (p 0.084, n 18). robust.
- cell type
- strongest in OPCs: -0.67 (p 0.0022, n 18) vs +0.42 in dopamine neurons. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ABL2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up ABL2 · OPCs · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.65 p 0.021 (needs p < 7.8e-4)
Receipts
loading the receipts